Journal
FUTURE MEDICINAL CHEMISTRY
Volume 7, Issue 13, Pages 1793-1808Publisher
FUTURE SCI LTD
DOI: 10.4155/fmc.15.101
Keywords
-
Categories
Funding
- NIH [NS055925, NS072259, NS080294, NS060926]
- Salsbury Endowment (Iowa State University, IA, USA)
- CureSMA [DID1214]
- Muscular Dystrophy Association [255785]
Ask authors/readers for more resources
Spinal muscular atrophy (SMA) is a major neurodegenerative disorder of children and infants. SMA is primarily caused by low levels of SMN protein owing to deletions or mutations of the SMN1 gene. SMN2, a nearly identical copy of SMN1, fails to compensate for the loss of the production of the functional SMN protein due to predominant skipping of exon 7. Several compounds, including antisense oligonucleotides (ASOs) that elevate SMN protein from SMN2 hold the promise for treatment. An ASO-based drug currently under Phase III clinical trial employs intronic splicing silencer N1 (ISS-N1) as its target. Cumulative studies on ISS-N1 reveal a wealth of information with significance to the overall therapeutic development for SMA. Here, the authors summarize the mechanistic principles behind various antisense targets currently available for SMA therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available